The Medicines Co. has acquired Rempex Pharmaceuticals, Inc., gaining several anti-infective assets, including Carbavance, Minocin IV, RPX-602, and a preclinical developmental program of novel investigational agents. The Medicines Co. paid Rempex equity holders $140 million upfront at closing and has agreed to pay $214 million for certain development and regulatory approval milestones, as well as $120 million in commercial milestones.   Carbavance is an investigational agent combining a novel bet...